IP Library Granted Patent US 7,354,934
Granted Patent B2
US 7,354,934 · App. 11/301,725 · Granted Apr 8, 2008

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,354,934
App. No.
11/301,725
Granted
Apr 8, 2008
Kind
B2
Abstract

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Claims (110)

1. A compound of the formula

or a pharmaceutically acceptable salt thereof; and including any stereoisomeric forms thereof;

wherein n4 is 2-4;

each R 1 is independently H, halo, alkyl, alkoxy, or CF 3 ;

each R 2 is independently H or alkyl;

R 3 is H, alkyl, alkenyl, arylalkyl, or aryl;

each R 4 is independently H or alkyl, or the two R 4 groups may be taken together with the ring to which they are attached to form an optionally substituted 6-membered aromatic or heteroaromatic ring; and

each R 6 is independently H, arylalkyl, acyl, arylacyl, or arylsulfonyl, wherein the aryl moieties thereof optionally contain one or more heteroatoms selected from the group consisting of O, S, and N.

2. The compound of claim 1 wherein each R 1 is.

3. The compound of claim 1 wherein each R 2 is.

4. The compound of claim 1 wherein R 2 is H.

5. The compound of claim 1 wherein the two R 4 groups may be taken together with the ring to which they are attached to form an optionally substituted phenyl ring.

6. The compound of claim 1 wherein each R 6 is.

7. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 , in admixture with a pharmaceutically acceptable excipient.

8. A compound selected from the group consisting of

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-ethane-1,2-diamine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 2 -(5-nitro-pyridin-2-yl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-ethane-1,2-diamine

N 1 -(6-2-[(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-ethylamino}-pyridin-3-yl)-acetamide;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-propane-1,3-diamine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 2 -pyridin-2-ylmethyl-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-ethane-1,2-diamine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N′-(1H-benzimidazol-2-ylmethyl)-N′-(S)-5,6,7,8-tetrahydro-quinolin-8-yl-butane-1,4-diamine;

N 1 -(1-Methyl-1H-benzoimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -[5-(4-Fluoro-phenyl)-1H-imidazol-2-ylmethyl]-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-N-benzyl-1,4-butanediamine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 4 -pyridin-2-ylmethyl-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 4 -(1H-indol-3-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

1-N′-[4-(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-aminobutane-N,N-dimethylformamidine;

N-{4-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyl}1-guanidine;

N′-(1H-benzimidazol-2-ylmethyl)-N′-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine-N-(2-pyridinyl)-sulfonamide;

N-(1H-benzoimidazol-2-ylmethyl)-N′-pyrimidin-2-ylmethyl-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N-(1H-benzoimidazol-2-ylmethyl)-N′-(1H-imidazol-2-yl)-N-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-benzimidazol-2-ylmethyl)-N 4 -(1H-indol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine;

(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(N,N-dimethyl-4-amino-but-1-yl)-amine;

(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(N-allyl-4-amino-but-1-yl)-amine;

(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(N-methyl-4-amino-but-1-yl)-amine;

N′-(1H-imidazol-2-ylmethyl)-N′-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N-{4-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butyl}-benzenesulfonamide;

(2S)-2-Amino-5-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-pentanoic acid;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 4 -cyclopropyl-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N′-(1H-benzimidazol-2-ylmethyl)-3-methyl-3-phenyl-N′-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-phenyl-1-aminobut-4-yl)-amine;

(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-aminobutan-3-ol-4-yl)-amine;

(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-amino-3-fluoro-butan-4-yl)-amine;

(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(5-amino-pent-1-yl)-amine;

(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(6-amino-hex-1-yl)-amine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 1 -(R)-5,6,7,8-tetrahydro-quinolin-8-yl-butane-1,4-diamine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-2-methylene-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-benzimidazol-2-ylmethyl)-3,3-difluoro-N 1 -(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-benzimidazol-2-ylmethyl)-2,2-difluoro-N 1 -(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine;

(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-amino-2-(O-methyloxime)-butan-4-yl)-amine:

(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-(1-amino-2-methylenyl-butan-4-yl)-amine;

(1H-benzimidazol-4-methoxy-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(1-aminobutan-4-yl)-amine;

N 1 -(1H-Benzimidazol-2-ylmethyl)-N 1 -(4-methoxy-5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-benzimidazol-2-ylmethyl)-N 1- (3-methoxy-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine;

N 1 -(1-Methyl-1H-benzoimidazol-2-ylmethyl)-N 1 -(S)-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-benzimidazol-2-ylmethyl)-N 1 -(2-chloro-5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-Benzoimidazol-2-ylmethyl)-N 1 -(2-methyl-5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine;

N 1 -(5,6-dimethyl-1H-benzimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -[1-(1H-Benzimidazol-2-yl)-ethyl]-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(4-fluoro-1H-benzimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(4-Methoxy-1H-benzoindiazol-2-ylmethyl)-N 1 -(S)-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(4-methyl-1H-benzoimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(4,5-dimethyl-1H-benzoimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quionlin-8-yl)-butane-1,4-diamine;

N 1 -(6-Fluoro-1H-benzimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-imidazo[4,5-b]pyridin-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1H-imidazo[4,5-c]pyridin-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(5-trifluoromethyl-1H-benzoimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1-allyl-1H-benzoimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1-Allyl-1H-benzimidazol-2-ylmethyl)-N 1 -(S)-5,6,7,8-tetrahydro-quinolin-8-yl-butane-1,4-diamine;

N 1 -(1-cyclopropylmethyl-1H-benzoimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1-pyridin-2-ylmethyl-1H-imidazol-2-ylmethyl)-N 1- (5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(4-methyl-1H-imidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1-isopropyl-1H-imidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -[1-(2-methoxy-ethyl)-1H-imidazol-2-ylmethyl]-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(4-methyl-1-propyl-1H-imidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine;

N 1 -(1-propyl-1H-imidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine;

N 1 -(1-methyl-1H-imidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)butane-1,4-diamine;

N 1 -(1-allyl-1H-imidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydroquinolin-8-yl)-butane-1,4-diamine;

N 1 -(4-Methoxymethyl-1H-imidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine);

N 1 -(1-Allyl-1H-imidazol-2-ylmethyl)-N 1 -(S)-5,6,7,8-tetrahydro-quinolin-8-yl-butane-1,4-diamine;

N 1 -{2-[(1H-Benzimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-ethyl}-guanidine;

{4-[(1H-Benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-butylamino}-acetic acid methyl ester;

pyrazine-2-carboxylic acid }4-[(1H-benzimidazol-2-ylmethyl)-(S)-5,6,7,8-tetrahydro-quinolin-8-yl-amino]-butyl}-amide;

Pyridine-2-carboxylic acid {3-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-amide;

Isoquinoline-3-carboxylic acid {3-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-amide;

N-{3-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-6-hydroxy-nicotinamide;

N-3-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-benzamide;

N-{3-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-5-bromo-nicotinamide;

Cinnoline-4-carboxylic acid-13-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-amide;

N-{4-[1H-benzolimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-butyl}-6-hydroxynicotinamide;

N-{4-[(1H-benzolimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-butyl}-benzamide;

pyridine-2-carboxylic acid {4-[1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-butyl}-amide;

N-{4-[(1H-Benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-butyl}-5-bromo-nicotinamide;

quinoline-2-carboxylic acid {2-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-butyl}-amide;

cinnoline-4-carboxylic acid {4-[(1H-benzoimidazol-2-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-yl)-amino]-butyl}-amide;

N-{2-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-ethyl}-3,5-dicliloro-isonicotinamide;

N-{3-[(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-3,5-dicliloro-isonicotinamide;

N-{4-[(1-allyl-1H-benzimidazol-2-ylmethyl)-(S)-5,6,7,8-tetrahydro-quinolin-8-ylamino]-butyl}-3,5-dicliloro-isonicotinamide;

N-{4-[(1H-benzimidazol-2-ylmethyl)-(R)-5,6,7,8-tetrahydro-quinolin-8-yl-amino]-butyl}-3,5-dicliloro-isonicotinamide;

N-{4-[(1-allyl-1H-imidazol-2-ylmethyl)-(S)-5,6,7,8-tetrahydro-quinolin-8-ylamino]-butyl}-3,5-dicliloro-isonicotinamide;

N-{4-[(1H-Benzimidazol-2-ylmethyl)-(S)-5,6,7,8-tetrahydro-quinolin-8-yl-amino]-butyl}-acetamide;

{4-[(1H-Benzimidazol-2-ylmethyl)-(S)-5,6,7,8-tetrahydro-quinolin-8-yl-amino]-butyl}-urea;

pyrazine-2-carboxylic acid {3-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-amide;

N-{3-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-propyl}-guanidine;

{3-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-propyl}-urea; and

{2-[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amino]-ethyl}-urea;

or a pharmaceutically acceptable salt thereof.

9. A compound which is N 1 -(1H-Benzimidazol-2-ylmethyl)-N 1 -(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine or a pharmaceutically acceptable salt thereof.

10. The compound of claim 9 as a hydrobromide salt.

Assignments (1)
MERGER AND CHANGE OF NAME Recorded Sep 19, 2014
From: ANORMED INC.; DEMATAL CORP.
To: ANORMED CORPORATION
Reel/Frame 033782/0221 →